Polymer architecture is exploited as an alternative to glycan synthesis to enhance selectivity towards pathogenic lectins.
No takes yet. Share an insight, caveat, or question.
Jones et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: